{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=30", "query": { "condition": "Advanced/Metastatic", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 3818, "total_pages": 382, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T18:18:44.545Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04136808", "title": "An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Locally Advanced or Metastatic Urothelial Carcinoma (UC)" ], "interventions": [ { "name": "enfortumab vedotin (EV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 15, "location_summary": "Los Angeles, California • Santa Monica, California • Santa Rosa, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04136808" }, { "nct_id": "NCT03132155", "title": "QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Sarcoma" ], "interventions": [ { "name": "AMG 337", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NantPharma, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 8, "start_date": "2018-08-29", "completion_date": "2021-09-21", "has_results": true, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 2, "location_summary": "El Segundo, California • Houston, Texas", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03132155" }, { "nct_id": "NCT02893917", "title": "Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Stage IV Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 90, "start_date": "2017-08-11", "completion_date": "2027-05-31", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 16, "location_summary": "La Jolla, California • Sacramento, California • San Diego, California + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02893917" }, { "nct_id": "NCT06669117", "title": "FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "MET Alteration" ], "interventions": [ { "name": "VERT-002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2024-10-22", "completion_date": "2032-10-01", "has_results": false, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Canton, Ohio • Nashville, Tennessee", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Canton", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06669117" }, { "nct_id": "NCT04940052", "title": "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Differentiated Thyroid Cancer (DTC)" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trametinib Placebo", "type": "DRUG" }, { "name": "Dabrafenib placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 153, "start_date": "2021-11-15", "completion_date": "2027-05-25", "has_results": true, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 2, "location_summary": "Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04940052" }, { "nct_id": "NCT01630733", "title": "A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Custirsen", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Achieve Life Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 664, "start_date": "2012-10-24", "completion_date": "2016-11-17", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 14, "location_summary": "Boynton Beach, Florida • Orlando, Florida • Athens, Georgia + 10 more", "locations": [ { "city": "Boynton Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Hazard", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01630733" }, { "nct_id": "NCT04656652", "title": "Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "DS-1062a", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 605, "start_date": "2020-12-21", "completion_date": "2027-02-15", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 32, "location_summary": "Chandler, Arizona • Anaheim, California • Glendale, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04656652" }, { "nct_id": "NCT04538664", "title": "A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Amivantamab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 308, "start_date": "2020-10-13", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 17, "location_summary": "Duarte, California • Orange, California • Santa Monica, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04538664" }, { "nct_id": "NCT01154452", "title": "Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Alveolar Soft Part Sarcoma", "Adult Angiosarcoma", "Adult Desmoplastic Small Round Cell Tumor", "Adult Epithelioid Hemangioendothelioma", "Adult Epithelioid Sarcoma", "Adult Extraskeletal Myxoid Chondrosarcoma", "Adult Extraskeletal Osteosarcoma", "Adult Fibrosarcoma", "Adult Leiomyosarcoma", "Adult Liposarcoma", "Adult Malignant Mesenchymoma", "Adult Malignant Peripheral Nerve Sheath Tumor", "Adult Rhabdomyosarcoma", "Adult Synovial Sarcoma", "Adult Unclassified Pleomorphic Sarcoma", "Chondrosarcoma", "Clear Cell Sarcoma of the Kidney", "Conjunctival Kaposi Sarcoma", "Dermatofibrosarcoma Protuberans", "Gastrointestinal Stromal Tumor", "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Metastatic Osteosarcoma", "Ovarian Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Kaposi Sarcoma", "Recurrent Osteosarcoma", "Recurrent Uterine Corpus Sarcoma", "Small Intestine Leiomyosarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Uterine Sarcoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Uterine Sarcoma", "Unclassified Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2010-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2018-08-15", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154452" }, { "nct_id": "NCT03017833", "title": "Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Refractory Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2018-03-12", "completion_date": "2022-12-21", "has_results": false, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-10-30T18:18:44.545Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03017833" } ] }